新医学
新醫學
신의학
NEW CHINESE MEDICINE
2013年
12期
854-856
,共3页
食管癌%电视胸腔镜手术%疗效
食管癌%電視胸腔鏡手術%療效
식관암%전시흉강경수술%료효
Esophageal carcinoma%Video-assisted thoracic surgery%Therapeutic effects
目的:比较全电视胸腔镜(VATS )下食管切除术治疗中、上段Ⅰ、Ⅱ、Ⅲa期食管癌与传统开放式食管切除术的手术效果。方法收集因食管癌行食管切除术的61例患者手术资料,其中VATS下行食管切除术治疗食管胸中、上段癌32例(VATS组),同期完成的传统开放式食管切除术29例(对照组),比较两组患者的围手术期指标及术后并发症发生情况。结果 VATS组术中出血量少于对照组,术后第1日引流量、术后引流总量、胸腔闭式引流时间均比对照组明显缩短,两组比较差异均有统计学意义(P<0.05);两组在手术时间、淋巴结清扫个数比较差异无统计学意义(P>0.05)。结论对于Ⅰ、Ⅱ、Ⅲa期食管癌,采用VATS下食管切除术的创伤及并发症较少,优于传统开放式手术。
目的:比較全電視胸腔鏡(VATS )下食管切除術治療中、上段Ⅰ、Ⅱ、Ⅲa期食管癌與傳統開放式食管切除術的手術效果。方法收集因食管癌行食管切除術的61例患者手術資料,其中VATS下行食管切除術治療食管胸中、上段癌32例(VATS組),同期完成的傳統開放式食管切除術29例(對照組),比較兩組患者的圍手術期指標及術後併髮癥髮生情況。結果 VATS組術中齣血量少于對照組,術後第1日引流量、術後引流總量、胸腔閉式引流時間均比對照組明顯縮短,兩組比較差異均有統計學意義(P<0.05);兩組在手術時間、淋巴結清掃箇數比較差異無統計學意義(P>0.05)。結論對于Ⅰ、Ⅱ、Ⅲa期食管癌,採用VATS下食管切除術的創傷及併髮癥較少,優于傳統開放式手術。
목적:비교전전시흉강경(VATS )하식관절제술치료중、상단Ⅰ、Ⅱ、Ⅲa기식관암여전통개방식식관절제술적수술효과。방법수집인식관암행식관절제술적61례환자수술자료,기중VATS하행식관절제술치료식관흉중、상단암32례(VATS조),동기완성적전통개방식식관절제술29례(대조조),비교량조환자적위수술기지표급술후병발증발생정황。결과 VATS조술중출혈량소우대조조,술후제1일인류량、술후인류총량、흉강폐식인류시간균비대조조명현축단,량조비교차이균유통계학의의(P<0.05);량조재수술시간、림파결청소개수비교차이무통계학의의(P>0.05)。결론대우Ⅰ、Ⅱ、Ⅲa기식관암,채용VATS하식관절제술적창상급병발증교소,우우전통개방식수술。
Objective To compare the therapeutic effects between video-assisted thoracic surgery (VATS)and thoractomy for radical operation in patients with stage I、II and IIIa esophageal cancer. Methods Sixty-one patients with stage I、II and IIIa esophageal cancer were retrospectively reviewed,who underwent with either VATS radical operation (VATS group,n=32)or standard radical operation via thoractomy (open group,n=29). Operative characteristics and postoperative courses were compared between two groups. Re-sults In two groups,there were no significant differences in the number of meditational Lymph node resection and the operation time are (P>0.05 ). The total volume of thoracic cavity drainage after operation,the volume of blood loss,the time of postoperative chest tube and the complications,were statistically significant between two groups (P<0.05 ). Conclusion Complete video-assisted thoracic surgery is safe and effective in patients with stage I、II and IIIa esophageal cancer.